Related by context. All words. (Click for frequent words.) 78 Phase Ib clinical 78 Phase Ib 77 Phase 2a trial 77 phase IIa clinical 76 Phase 2b trial 76 Phase Ib study 76 Phase 1b clinical 76 phase IIb 76 Phase IIa trial 75 Phase 2b study 75 Phase 2a clinical 75 Phase 2a 75 Phase 1b 75 phase IIb trial 75 dose escalation trial 75 phase IIb clinical 74 Phase Ib II 74 phase IIa 73 evaluating tivozanib 73 oral ridaforolimus 73 alvespimycin 73 Phase IIIb clinical 73 Phase IIb clinical 73 HGS# 73 Phase IIa clinical 73 Phase IIb 73 INCB# [001] 72 phase Ib 72 Phase III clinical 72 FOLFOX6 chemotherapy regimen 72 Phase IIa 72 Phase IIb trials 72 dose escalation Phase 72 Phase 2b clinical 72 Phase IIa trials 72 pivotal Phase III 72 JAK inhibitor 72 phase IIb study 71 Phase 1a clinical 71 pharmacokinetic PK study 71 Phase 1a 71 deforolimus 71 multicenter Phase II 71 Phase Ia 71 CR# vcMMAE 71 phase 2a 71 forodesine 71 dose escalation study 71 ganetespib 71 confirmatory Phase III 71 Plicera 71 FOLOTYN ® 71 oral prodrug 71 Phase 2b clinical trials 71 Phase #b/#a 71 blinded randomized placebo controlled 71 phase Ib clinical 71 IIa trial 70 Phase 2b 70 Phase IIb trial 70 multiple ascending dose 70 multicenter Phase 70 pertuzumab 70 placebo controlled clinical 70 Phase #/#a 70 randomized Phase IIb 70 elotuzumab 70 CRLX# 70 ongoing Phase 1b 70 oral deforolimus 70 registrational 69 lomitapide 69 viral kinetic 69 Phase III trials 69 Phase IIb clinical trials 69 phase IIb III 69 virus HCV protease inhibitor 69 single ascending dose 69 Phase #b/#a clinical 69 Phase III pivotal 69 SUCCEED trial 69 R#/MEM # 69 APTIVUS 69 clinical pharmacology studies 69 teriflunomide 69 Phase Ib clinical trials 69 NVA# 69 bicifadine 69 OvaRex R 68 PRT# 68 neratinib 68 Phase IIIb study 68 pharmacokinetics PK 68 NGX# 68 placebo controlled Phase III 68 PXD# 68 fosbretabulin 68 enzastaurin 68 IMA# 68 tolerated dose MTD 68 AEG# 68 cannabinor 68 dose cohorts 68 Blinatumomab 68 EOquin TM 68 pivotal bioequivalence 68 pharmacokinetic studies 68 Phase III Clinical Trial 68 pomalidomide 68 vidofludimus 68 Tanespimycin 68 PEG PAL 68 docetaxel Taxotere R 68 PRX # 68 PSN# [002] 68 Phase III 68 TMC# C# 68 Phase 1b clinical trials 68 clinical trial 68 Phase IIB 68 varespladib 68 investigational protease inhibitor 68 Novolimus 68 axitinib 68 placebo controlled Phase 68 Zenvia ™ 68 randomized Phase III 68 Omacetaxine 68 velafermin belinostat 68 RSD# oral 68 MEND CABG 68 Azedra 68 HGS ETR1 68 AIR CF1 68 plus Copegus R 68 registrational trial 68 Archexin 68 CRMD# 68 Phase III confirmatory 67 mapatumumab 67 investigational pan BCR 67 dose escalation clinical 67 PRTX 67 Phase IIIb 67 trodusquemine 67 tanespimycin 67 BCX# 67 velafermin 67 PDE4 inhibitor 67 Personalized Immunotherapy 67 oral salmon calcitonin 67 prospective observational 67 generation PNP inhibitor 67 Androxal TM 67 AEGR 67 bendamustine 67 Phase 2b Clinical Trial 67 celgosivir 67 PEG SN# 67 ENDEAVOR IV 67 Phase III clinical trials 67 KRN# 67 pharmacokinetic PK 67 HuMax EGFr 67 Imprime PGG 67 confirmatory Phase 3 67 midstage trials 67 MAGE A3 ASCI 67 diabetic neuropathic pain 67 midstage clinical 67 YONDELIS 67 SCH # 67 TMC# [002] 67 Deforolimus 67 GALNS 67 double blinded placebo 67 Aflibercept 67 ADAGIO study 67 Bicifadine 67 maximally tolerated dose 67 rALLy clinical trial 67 APEX PD 67 double blinded randomized 67 LymphoStat B TM 67 Clolar ® 67 EDEMA3 67 urocortin 2 67 Phase Ib IIa 67 pivotal Phase 67 dextromethorphan quinidine 67 Hsp# Inhibitor 67 Traficet EN 67 Cloretazine R VNP#M 67 II Clinical Trial 67 AZILECT R 67 lintuzumab 67 SAR# [004] 66 Ophena TM 66 multicenter randomized placebo controlled 66 liposomal formulation 66 ZYBRESTAT 66 Darusentan 66 BRIM3 66 randomized Phase 66 ADVANCE PD 66 initiate Phase IIb 66 selective androgen receptor modulator 66 orally bioavailable 66 Genz # 66 Phase #b/#a trial 66 trastuzumab Herceptin R 66 Panzem R NCD 66 COMFORT II 66 GLPG# 66 GSK# [002] 66 dose cohort 66 MAA submission 66 CoFactor 66 teduglutide 66 OMP #M# 66 Urocortin 2 66 TOCOSOL Paclitaxel 66 sunitinib malate 66 ruxolitinib 66 plasma kallikrein inhibitor 66 Tarceva TM 66 randomized multicenter Phase III 66 LibiGel Phase III 66 Tezampanel 66 investigational compound 66 multicenter Phase III 66 galiximab 66 pharmacodynamic effects 66 Panzem R 66 Phase IIb Trial 66 multicenter clinical 66 NP2 Enkephalin 66 TACI Ig 66 GAMMAGARD 66 HCV SPRINT 66 ILLUMINATE 66 safety tolerability pharmacokinetic 66 investigational oral 66 Phase III Clinical Trials 66 nonclinical studies 66 Bezielle 66 Phase IIb III 66 brivaracetam 66 lucinactant 66 davunetide intranasal AL 66 Phase #/#a trial 66 LCP AtorFen 66 Quinamed 66 preclinical efficacy 66 IDX# 66 Sapacitabine 66 intranasal formulation 66 Clonicel 66 riociguat 66 NO# [002] 66 Mipomersen 66 HCV protease inhibitor 66 ISIS # 66 JAK2 inhibitor 66 masked placebo controlled 66 IL# PE#QQR 66 HuMax CD4 66 metaglidasen 66 RSD# 66 relapsed refractory multiple myeloma 66 Initiate Phase 66 generation Hsp# inhibitor 66 metastatic castration resistant 66 PEG Interferon lambda 65 Laquinimod 65 rNAPc2 65 randomized controlled Phase 65 obatoclax 65 dacetuzumab 65 lorvotuzumab mertansine 65 oral rivaroxaban 65 Romidepsin 65 Xeloda ® 65 leading oral taxane 65 metastatic hormone refractory 65 PHX# 65 relapsed MM 65 TBC# 65 bortezomib Velcade R 65 OvaRex ® MAb 65 Intervention Effectiveness 65 randomized Phase 2b 65 DermaVir Patch 65 budesonide foam 65 incyclinide 65 DAVANAT 65 initiate Phase 2b 65 non nucleoside inhibitor 65 tezampanel 65 Pimavanserin 65 Phase 2b Trial 65 TLK# 65 AeroLEF TM 65 INSPIRE Trial Phase III 65 KNS # 65 GW# [003] 65 PSMA ADC 65 PROSTVAC ® 65 Spiegelmer ® 65 phase IIIb 65 generation purine nucleoside 65 Phase 2b kidney transplant 65 GLP toxicology studies 65 ascending doses 65 HuMax CD# 65 histamine dihydrochloride 65 TG# [003] 65 TG MV 65 trastuzumab DM1 T DM1 65 adecatumumab MT# 65 huC# DM4 65 orally administered inhibitor 65 pharmacodynamic profile 65 evaluating mipomersen 65 HCD# [002] 65 romidepsin 65 Zenvia Phase III 65 BAY #-# 65 Myocet 65 preclinically 65 PFO migraine 65 multicenter phase 65 Zerenex 65 ARIKACE 65 Cloretazine 65 receptor tyrosine kinase inhibitor 65 Tyrima 65 R#/MEM 65 GetGoal Phase III 65 bortezomib Velcade 65 Phase 2a clinical trials 65 compound INCB# 65 Initiated Phase 65 EDEMA3 trial 65 treatment naive genotype 65 lumiliximab 65 Phase III Pivotal 65 Elotuzumab 65 Sym# 65 safety tolerability pharmacokinetics 65 Phase III Trial 65 Ozarelix 65 Phase IIb Clinical Trial 65 ularitide 65 unique alkylating agent 65 Pivotal Trial 65 Vicriviroc 65 INCB# [002] 65 investigational humanized monoclonal antibody 65 MGd 65 MEND CABG II 65 LY# [003] 65 PANVAC VF 65 TELINTRA 65 Pivotal Study 65 RG# ITMN 65 HGS ETR2 65 Alzhemed TM 65 RH1 65 RGB # 65 ThermoDox ® 65 RG# [001] 65 refractory CLL 65 ToGA 65 Phase III multicenter 65 Corlux 65 eniluracil 65 XL# XL# XL# 65 treatment naïve genotype 65 #th Annual Interscience 65 Presents Preclinical 65 Tracleer R 64 Triolex 64 GLYX 64 Ixempra 64 tolerability 64 GOUT 64 Amrubicin 64 entinostat 64 LibiGel ® 64 vosaroxin 64 preclinical studies 64 vicriviroc 64 ofatumumab 64 TOLAMBA 64 mertansine 64 randomized placebo controlled 64 Phase 2b randomized 64 XmAb# 64 azilsartan medoxomil 64 HQK 64 CYT# potent vascular disrupting 64 Capesaris 64 BRIM2 64 CCX# 64 Allovectin 7 64 RE SURGE 64 confirmatory clinical 64 Varespladib 64 Lisofylline LSF 64 ENMD # 64 ELACYT 64 Aurora kinase inhibitor 64 GRAVITAS trial 64 ZYBRESTAT fosbretabulin 64 IND submission 64 bevirimat Study 64 Cloretazine ® 64 BOLDER II 64 omega interferon 64 AAG geldanamycin analog 64 Daclizumab 64 Chemophase 64 IMC A# 64 Zoraxel 64 MEK inhibitor RDEA# 64 Xelox 64 nab paclitaxel 64 lesinurad 64 Combination REOLYSIN R 64 dose escalation 64 SILENOR 64 Tarvacin TM 64 DU #b 64 Completes Patient Enrollment 64 label dose escalation 64 ocrelizumab 64 CCR9 antagonist 64 Vilazodone 64 CALGB 64 Annamycin 64 Safinamide 64 Fodosine 64 ORMD 64 investigational HCV polymerase 64 Carfilzomib 64 ascending dose 64 Asentar 64 PDX pralatrexate 64 ANCHOR trial 64 peginesatide 64 pradefovir 64 TASKi2 64 NOX E# 64 OHR/AVR# 64 acyclovir Lauriad R 64 ZOLINZA 64 huN# DM1 64 AZILECT ® 64 refractory chronic lymphocytic 64 Pivotal Phase III 64 albinterferon alfa 2b 64 sNDA submission 64 novel VDA molecule 64 Phase IIa clinical trials 64 placebo controlled 64 Phase III placebo controlled 64 nucleotide analog 64 hypoxia activated prodrug 64 DR Cysteamine 64 Microplasmin 64 PNP inhibitor 64 OncoGel 64 desvenlafaxine succinate 64 elacytarabine 64 Ophena 64 polymerase inhibitor 64 OncoVex 64 CTAP# Capsules 64 SPIRIT FIRST 64 ThermoDox R 64 rilonacept 64 Lixivaptan 64 lintuzumab SGN 64 initiate Phase Ib 64 CG# [003] 64 Forodesine HCl 64 Trofex 64 ZD# [001] 64 ataluren 64 nalbuphine ER 64 Phenoptin 64 multicentre randomized 64 Fx #A 64 DDP# 64 Pazopanib 64 pharmacokinetic profile 64 MEK inhibitor 64 Exelixis compounds 64 ABSORB trial 64 SPRYCEL ® 64 pharmacodynamic PD 64 Abiraterone acetate 64 tesmilifene 64 Multiple Ascending Dose 64 erlotinib Tarceva ® 64 placebo controlled clinical trials 64 Phase 1b dose escalation 64 randomized multicenter 64 radiation sensitizer 64 edoxaban 64 miconazole Lauriad ® 64 tolerability profile 64 PS# [001] 64 ritonavir boosted 64 Phase III ALLEGRO 64 docetaxel chemotherapy 64 omacetaxine mepesuccinate 64 docetaxel Taxotere ® 64 Pivotal Phase 64 APTIVUS r 64 MYTHOS trial 64 ThermoDox ® clinical 64 HuLuc# 64 Xanafide 64 CA4P 64 Phase III LibiGel 64 Elagolix 64 XL# anticancer compounds 64 CHAMPION PCI 63 QLT# 63 adalimumab Humira 63 ATL# [001] 63 candidates Dyloject TM 63 LIALDA 63 Dapagliflozin 63 sorafenib Nexavar 63 PI3K/Akt pathway inhibitor 63 Ocrelizumab 63 REOLYSIN ® 63 PF # [002] 63 sorafenib tablets 63 PEGylated interferon beta 1a 63 SABCS 63 DEB# 63 rALLy trial 63 peripherally acting 63 IAP inhibitors 63 PA# [002] 63 OMNARIS HFA 63 Amplimexon 63 Pegasys R 63 initiated Phase Ib 63 ISTODAX ® 63 PKC# 63 blind randomized placebo 63 assessing T DM1 63 Denufosol 63 orally dosed 63 albiglutide 63 Cethromycin 63 Meets Primary Endpoint 63 double blind placebo 63 oral FTY# 63 CEQ# 63 IPL# 63 Aryplase 63 pharmacokinetic 63 trastuzumab emtansine T DM1 63 pharmacodynamics 63 IIa clinical 63 pan HDAC inhibitor 63 APPRAISE 63 subcutaneous formulation 63 MOZOBIL 63 Ceflatonin R 63 VNP#M 63 Pafuramidine 63 clevidipine 63 atrasentan 63 eltrombopag 63 randomized multicenter trial 63 AVADO 63 MLN# 63 CLARITY study 63 AVE# 63 balsalazide tablet 63 DXL# 63 lead Aganocide compound 63 initiate Phase 1b 63 anticancer compound 63 Pertuzumab 63 Elvitegravir 63 IIa trials 63 RLY# 63 uric acid lowering 63 REVLIMID lenalidomide 63 Phase III randomized controlled 63 Enzastaurin 63 dirucotide 63 Pegasys ® 63 Amigal 63 solithromycin 63 protein kinase inhibitor 63 AzaSite Plus 63 aclidinium bromide 63 elagolix 63 torezolid phosphate 63 IMGN# 63 ACTEMRA TM 63 BRAF inhibitor 63 TRO# 63 Initiates Enrollment 63 muraglitazar 63 rindopepimut 63 tezampanel NGX# 63 CLORETAZINE TM VNP#M 63 Degarelix 63 Ereska 63 farletuzumab 63 HspE7 63 Factor VIIa 63 oral picoplatin 63 administered subcutaneously 63 Aurexis 63 ProSavin 63 Teriflunomide 63 tolevamer 63 pegylated interferon alfa 2a 63 Phase IIA 63 fostamatinib 63 MabCampath 63 Alocrest 63 clinical trials 63 Urocidin 63 cathepsin K inhibitor 63 ZEVALIN ® 63 ProLindac 63 MERLIN TIMI 63 CIMZIA TM 63 Seliciclib 63 active comparator 63 Serada 63 VITAL Trial 63 PREOS 63 BLA filing 63 OXi# 63 aplindore 63 Dose escalation 63 PROMACTA 63 cetuximab Erbitux ® 63 multicenter placebo controlled 63 CB2 selective receptor agonist 63 aclidinium 63 Anturol TM 63 Triapine 63 evaluating Nexavar 63 histone deacetylase HDAC inhibitor 63 Locteron ® 63 REG2 63 LUMINATE 63 Diabetic Macular Edema DME 63 octreotide implant 63 PROSTVAC TM 63 efficacy tolerability 63 oxymorphone ER 63 multicenter multinational 63 BioNumerik 63 hyperphenylalaninemia HPA due 63 sorafenib Nexavar ® 63 favorable pharmacokinetic profile 63 cell lymphoma CTCL 63 Pharmacokinetics PK 63 oral formulation 63 OvaRex 63 multicenter randomized double 63 LEUKINE 63 Viramidine 63 ulimorelin 63 ospemifene 63 Targretin 63 relapsed multiple myeloma 63 Aliskiren 63 dexpramipexole 63 placebo controlled randomized 63 subcutaneously administered 63 reslizumab 63 ZACTIMA 63 analgesic efficacy 63 By JENNIFER LEARN 63 hyaluronidase enzyme 63 inhaled formulation 63 blinded placebo controlled 63 Dyloject TM 63 Acute Ischemic Stroke 63 Zemplar Capsules 63 intermittent dosing 63 Onrigin 63 MyVax R 63 doxorubicin docetaxel 63 NABTT 63 FavId 63 candidate CRLX# 63 EmbraceAC 63 Randomized Phase 63 Allovectin 7 R 63 IGF 1R inhibitor 63 cariprazine 63 CBLC# 63 prospective randomized placebo 63 Phase III randomized 63 SUTENT ® 63 zanolimumab 63 Perforomist ™ Inhalation Solution 63 Phase 2a Trial 63 basal bolus regimen 63 adecatumumab 63 JAK2 Inhibitor 63 OncoVEX 63 cetuximab Erbitux R 63 Febuxostat 63 Phase III ADT 63 Ridaforolimus 63 MAP# 63 TO AVOID PREGNANCY WHILE 63 LCP Tacro 63 PEG IFN 63 prucalopride 63 EVIZON 63 Nanobody 63 superficial bladder cancer 63 Glufosfamide 63 CIMZIA ™ 63 Prostate AdenoCarcinoma Treatment 63 BARACLUDE R 63 Maximum Tolerated Dose 63 IMP# 63 Icatibant 63 pharmacokinetic pharmacodynamic 62 HepeX B TM 62 Initiates Phase II 62 arzoxifene 62 Golimumab 62 novel histone deacetylase 62 ganaxolone 62 Omnitarg 62 WX UK1 62 Oral NKTR 62 RDEA# 62 Dacogen injection 62 valopicitabine 62 Phase II 62 Relovair 62 tiapamil 62 PRIMO CABG 62 novel oral anticoagulant 62 vorinostat 62 sapacitabine 62 Ceflatonin 62 CAMPATH 62 Nexavar ® 62 R# #mg BID 62 Proellex TM 62 initiate Phase IIa 62 nitazoxanide 62 q8h 62 CCR5 mAb 62 inhibitor RG# 62 AIM HIGH 62 safinamide 62 fidaxomicin Phase 3 62 SNT MC# 62 Tykerb lapatinib 62 ponatinib 62 INCB# [003] 62 Hsp# inhibitor 62 alemtuzumab Campath 62 FASLODEX 62 relapsing remitting multiple sclerosis 62 EFAPROXYN 62 GRN# 62 PEARL SC 62 APOPTONE 62 RELOVAIR ™ 62 antibody MAb 62 L BLP# 62 AKT inhibitor 62 Ambrisentan 62 Initiates Phase III 62 telaprevir dosed 62 eprotirome 62 Cimzia TM 62 Genasense ® oblimersen 62 LIVALO 62 2 methoxyestradiol 62 Fludara ® 62 Thiovir 62 Phase III registrational 62 cystinosis patients 62 JANUVIA 62 Xcytrin R 62 AIR CF2 62 CANCIDAS 62 sitaxsentan 62 investigational hepatitis C 62 indibulin 62 viral kinetics 62 Sunovion 62 bevacizumab Avastin ® 62 Copegus ribavirin 62 beta 1a 62 Interferon beta 1a 62 LUX Lung 62 SinuNase TM 62 Duromist ™ 62 lenalidomide Revlimid 62 PRESEPT 62 Xcellerated T Cells 62 LymphoStat B 62 randomized clinical 62 ® natalizumab 62 European Sepsis Trial 62 Civacir 62 mGluR5 NAM 62 CDP# 62 BLA submission 62 FTY# fingolimod 62 MGCD# [001] 62 baminercept 62 IMC #B 62 BNC# 62 severe hypercholesterolemia 62 Diabetic Macular Edema 62 metformin sulfonylurea 62 ocular formulation 62 OMP #R# 62 CCX# B 62 TPI ASM8 62 Maximum Tolerated Dose MTD 62 Onconase 62 TRISENOX 62 Oracea TM 62 INT# [002] 62 thalidomide Thalomid 62 Neurodex 62 ChronVac C R 62 evaluating carfilzomib 62 cediranib 62 metastatic sarcomas 62 OncoVEX GM CSF 62 Augment Injectable 62 MKC# MKC# PP 62 ISTODAX 62 THR beta agonist 62 Phase #/#a clinical 62 lapatinib Tykerb 62 interferon gamma 1b 62 BLOOM DM 62 ORENCIA ® 62 tramiprosate Alzhemed TM 62 Presents Preclinical Data 62 Aclidinium 62 Myelodysplastic Syndrome MDS 62 PEGINTRON TM 62 SAR# [002] 62 otelixizumab 62 ORENCIA R 62 BCR ABL inhibitor 62 Gabapentin GR 62 HCV NS5B polymerase 62 mipomersen 62 AVONEX ® 62 investigational monoclonal antibody 62 visilizumab 62 liprotamase 62 dose regimens 62 regorafenib 62 Initiates Clinical Trial 62 pharmacodynamic properties 62 isavuconazole 62 class mGluR5 inhibitor 62 Dual Opioid 62 MYCAMINE 62 ELND# 62 placebo controlled studies 62 xanthine oxidase inhibitor 62 Cotara 62 alfa 2a 62 THALOMID 62 DASISION 62 Nexavar sorafenib 62 nucleoside analog 62 nanopharmaceutical 62 randomized discontinuation trial 62 pioglitazone HCl 62 registrational clinical 62 IIa clinical trial 62 controlled multicenter Phase 62 HCV RESPOND 2 62 pharmacokinetic parameters 62 Panzem NCD 62 non nucleoside HCV 62 PD LID 62 ALN TTR# 62 Iloperidone 62 CYCLOSET 62 BiTE R 62 StemEx 62 investigational antiplatelet agent 62 olaparib 62 Antiviral Activity 62 Prospective Randomized 62 glucokinase activator 62 initiated Phase 1b 62 Besivance 62 protease inhibitor PI 62 Valortim 62 CCR5 antagonist 62 EOquin 62 standard chemotherapy regimen 62 ARIKACE ™ 62 goserelin 62 unblind 62 Matrix Phase 2b 62 FOLFIRI chemotherapy 62 tasimelteon 62 oral antiviral 62 NXL# 62 Hedgehog antagonist 62 ® pioglitazone HCl 62 Zybrestat 62 gemcitabine Gemzar ® 62 BrachySil TM 62 Ostarine 62 daclizumab 62 AVASTIN 62 retaspimycin 62 transcriptase inhibitor NNRTI 62 EXPLORE Xa 62 Serdaxin 62 ACAPODENE 62 Prodarsan 62 glufosfamide 62 Cetuximab Erbitux 62 vapreotide acetate 62 Virulizin ® 62 GRNVAC1 62 RE LY ® 62 Pivotal Clinical Trial 62 MT#/MEDI-# 62 depsipeptide 62 Catena ® 62 highly selective inhibitor 62 Pharmacokinetic 62 Imprime PGG ® 62 MBP# [001] 62 RenalGuard System TM 62 CUSTOM III 62 Aplidin 62 Pralatrexate 62 BMS# 62 evaluating satraplatin 62 Rebif ® 62 NEBIDO 62 Silodosin 62 Tesetaxel 62 REVIVE Diabetes 62 Immunotherapeutic 62 corticosteroid dexamethasone 62 Velcade bortezomib 62 ENESTnd 62 NCCTG 62 SYMMETRY trial 62 Pegasys plus Copegus 62 dose dose escalation 62 telaprevir VX 62 EchoCRT 62 Actilon 62 alvimopan 62 Alinia 62 prospective multicenter randomized 62 HDAC Inhibitor 62 NSABP B 62 TKB# 62 dasatinib Sprycel ® 62 arsenic trioxide injection 62 denufosol 62 selective modulator 62 evaluating Actimmune 62 alefacept 62 ixabepilone 62 XL# XL# 62 safety tolerability 62 RE LY 62 cilengitide 62 opioid induced bowel dysfunction 62 mg RDEA# 62 LY# [002] 62 Phase 2a Study